Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Indaptus Therapeutics (NASDAQ: INDP ) got an update from the FDA. This allows it to move forward with a Phase 1 clinical trial. That trial is for Decoy20, which is designed to treat cancer tumors. Source: Bu...
Gainers: NeuroMetrix (NURO) +45%. Zealand Pharma (ZEAL) +18%. SIGA Technologies (SIGA) +16%. Indaptus Therapeutics (INDP) +15%. Immix Biopharma (IMMX) +13%. Losers: China SXT Pharmaceuticals (SXTC) -20%. Ocuphire Pharma (OCUP) -9%. Enanta Pharmaceu...
Indaptus Therapeutics (INDP) +22% on FDA nod to begin phase 1 trial of Decoy20 for solid tumors. Zealand Pharma (ZEAL) +19% announces positive results from phase 3 trial of dasiglucagon in pediatric patients with congenital hyperinsulinism. CBAK Energy Technology (CBAT)...
Indaptus Therapeutics (NASDAQ:INDP) said the U.S. Food and Drug Administration (FDA) cleared its Investigational New Drug (IND) application to begin a phase 1 trial of Decoy20 to treat patients with advanced solid tumors when currently approved therapies have failed. The company pla...
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for a Phase 1 clinical tri...
NEW YORK, May 18, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”) today announced that Jeffrey A. Meckler, Chief Executive Officer of Indaptus, will present a corporate overview at the H.C. Wainwright Global Investment Conference on W...
Indaptus Therapeutics press release (NASDAQ:INDP): Q1 GAAP EPS of -$0.41. Cash and cash equivalents of $33.21M For further details see: Indaptus Therapeutics GAAP EPS of -$0.41
Announces Submission of Investigational New Drug (IND) Application for Decoy20 On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Second Half of 2022 NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("...
NEW YORK, April 20, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”) today announced that Michael J. Newman, Ph.D., Founder and Chief Scientific Officer, will present at the 2 nd Annual Chronic HBV Drug Development Summit taking pl...
NEW YORK, March 23, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company”), today announced that Jeffrey Meckler, Chief Executive Officer, will participate in a pre-recorded presentation at the Maxim Group 2022 Virtual Growth Conference made...
News, Short Squeeze, Breakout and More Instantly...
Indaptus Therapeutics Inc. Company Name:
INDP Stock Symbol:
NASDAQ Market:
Indaptus Therapeutics Inc. Website:
- Chief Scientific Officer Dr. Newman to present initial clinical data that further validates Company’s “Pulse-Prime” hypothesis - Dr. Newman also named Chair of the Summit NEW YORK, June 11, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a...
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc, (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that its Chief Medical Officer, Roger Waltzman, M.D., will present an update on ...
Latest data from first and second cohorts support Company’s 'pulse-prime' approach, demonstrating rapid clearance, broad immune activation, and encouraging safety profile Poster Presented at American Society of Clinical Oncology Annual Meeting NEW YORK, June 03, 2024 (GLOBE...